A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction
Department
Internal Medicine
Document Type
Article
Publication Title
American Journal of Cardiovascular Disease
Abstract
Background: Heart failure with preserved ejection fraction is a complex clinical syndrome marked by different phenotypes and related comorbidities. Transthyretin amyloidosis is an underestimated phenotype. We aim to evaluate the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction.
Methods: This meta-analysis was conducted according to PRISMA guidelines. A search strategy was designed to utilize PubMed/ Medline, EMBASE, and Google scholar to locate studies whose primary objective was to analyze the prevalence of transthyretin amyloidosis in heart failure preserved ejection fraction.
Results: Of 271 studies initially identified, 5 studies comprising 670 patients were included in the final analysis. The prevalence of transthyretin amyloidosis was 11%. Patients with transthyretin amyloid cardiomyopathy were more likely to be males (RR 1.38; 95% CI 1.09 to 1.75; P< 0.01; I2=37%), and more likely to have low voltage criteria on ECG (RR 2.98; 95% CI 1.03 to 8.58; P=0.04; I2=75%) compared with transthyretin negative group. They also have higher SMD of age (SMD 0.73; 95% CI 0.48 to 0.97; P< 0.01; I2=0%), and NT-proBNP (SMD 0.48; 95% CI 0.02 to 0.93; P=0.04; I2=36%) compared with transthyretin negative group. On reported echocardiogram, they have higher SMD of mass index (SMD 0.77; 95% CI 0.27 to 1.27; P< 0.01; I2=65%), posterior wall thickness (SMD 0.92; 95% CI 0.62 to 1.21; P< 0.01; I2=0%), and septal wall thickness (SMD 1.49; 95% CI 0.65 to 2.32; P< 0.01; I2=87%) compared with transthyretin negative group.
Conclusion: Transthyretin amyloidosis affects 11% of HFpEF patients. Therefore, screening HFpEF patients at risk of cardiac amyloidosis is warranted.
First Page
102
Last Page
111
Volume
12
Issue
3
Publication Date
6-15-2022
PubMed ID
35873185
Recommended Citation
Magdi, M., Reda Mostafa, M., Alweis, R., & Baibhav, B. (2022). A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction. American Journal of Cardiovascular Disease, 12 (3), 102-111. Retrieved from https://scholar.rochesterregional.org/rrhpubs/1502
Comments
See full list of authors at journal website.